Christos N. Papandreou

9.4k total citations · 1 hit paper
124 papers, 5.1k citations indexed

About

Christos N. Papandreou is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christos N. Papandreou has authored 124 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 46 papers in Molecular Biology and 45 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christos N. Papandreou's work include Ubiquitin and proteasome pathways (23 papers), Prostate Cancer Treatment and Research (23 papers) and Peptidase Inhibition and Analysis (17 papers). Christos N. Papandreou is often cited by papers focused on Ubiquitin and proteasome pathways (23 papers), Prostate Cancer Treatment and Research (23 papers) and Peptidase Inhibition and Analysis (17 papers). Christos N. Papandreou collaborates with scholars based in Greece, United States and France. Christos N. Papandreou's co-authors include Laura Ladrón de Guevara, Junji Furuse, Alan P. Venook, Christopher J. Logothetis, Panagiotis J. Vlachostergios, Danai Daliani, Shi‐Ming Tu, Eleana Hatzidaki, Anna Patrikidou and Lance C. Pagliaro and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Christos N. Papandreou

119 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

2010 790 citations Alan P. Venook, Christos N. Papandreou et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christos N. Papandreou Greece	32	1.8k	1.7k	1.4k	1.1k	973	124	5.1k
Masato Nakamura Japan	44	3.1k 1.7×	3.1k 1.8×	1.4k 1.0×	1.5k 1.4×	1.5k 1.6×	401	7.9k
Diana Julie Leeming Denmark	48	1.8k 1.0×	1.2k 0.7×	1.5k 1.1×	1.7k 1.6×	859 0.9×	213	7.7k
Tsutomu Sato Japan	41	1.6k 0.9×	1.5k 0.9×	1.5k 1.1×	765 0.7×	492 0.5×	382	6.5k
Hui Luo China	43	2.4k 1.3×	2.7k 1.6×	1.3k 1.0×	340 0.3×	1.7k 1.7×	291	6.6k
Koji Miyanishi Japan	32	1.5k 0.8×	1.0k 0.6×	582 0.4×	781 0.7×	449 0.5×	151	4.0k
Mario Scartozzi Italy	44	1.7k 0.9×	3.7k 2.2×	2.1k 1.5×	953 0.9×	1.5k 1.5×	343	6.4k
Rishu Takimoto Japan	40	2.6k 1.5×	1.6k 0.9×	503 0.4×	755 0.7×	564 0.6×	155	5.8k
Georg Lurje Germany	37	1.2k 0.7×	2.0k 1.2×	1.1k 0.8×	972 0.9×	692 0.7×	162	4.7k
Xin‐Rong Yang China	48	3.3k 1.9×	3.5k 2.1×	1.2k 0.9×	1.7k 1.6×	2.9k 3.0×	181	9.3k

Countries citing papers authored by Christos N. Papandreou

Since Specialization

Citations

This map shows the geographic impact of Christos N. Papandreou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christos N. Papandreou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christos N. Papandreou more than expected).

Fields of papers citing papers by Christos N. Papandreou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christos N. Papandreou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christos N. Papandreou. The network helps show where Christos N. Papandreou may publish in the future.

Co-authorship network of co-authors of Christos N. Papandreou

This figure shows the co-authorship network connecting the top 25 collaborators of Christos N. Papandreou. A scholar is included among the top collaborators of Christos N. Papandreou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christos N. Papandreou. Christos N. Papandreou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dimitropoulos, Konstantinos, Louis L. Pisters, Christos N. Papandreou, et al.. (2023). The Impact of Enhanced Recovery after Surgery Protocol Implementationon Postoperative Pain Management in the Era of Opioid Crisis: The PostchemotherapyOpen RPLND Experience. Current Cancer Drug Targets. 23(11). 910–916. 2 indexed citations

Vlachostergios, Panagiotis J., et al.. (2021). Early mRNA Expression of Neuroendocrine Differentiation Signals Predicts Recurrence After Radical Prostatectomy: A Transcriptomic Analysis. World Journal of Oncology. 12(6). 232–239. 2 indexed citations

Karatzas, Anastasios, et al.. (2018). Primitive neuroectodermal tumor transformation of testicular teratoma. Urology Annals. 10(4). 413–413. 5 indexed citations

Christodoulou, Christos, Anna Kalogera‐Fountzila, Vasilios Karavasilis, et al.. (2017). Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Journal of Neuro-Oncology. 134(2). 443–451. 13 indexed citations

Marrero, Jorge A., Masatoshi Kudo, Alan P. Venook, et al.. (2016). Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. Journal of Hepatology. 65(6). 1140–1147. 264 indexed citations

Kudo, Masatoshi, Riccardo Lencioni, Jorge A. Marrero, et al.. (2016). Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: GIDEON observational study. Liver International. 36(8). 1196–1205. 36 indexed citations

Geschwind, Jean-François H., Masatoshi Kudo, Jorge A. Marrero, et al.. (2016). TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology. 279(2). 630–640. 94 indexed citations

Koutsoukos, Konstantinos, Kimon Tzannis, Christos Christodoulou, et al.. (2015). Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG). World Journal of Urology. 34(6). 853–857. 3 indexed citations

Σαμαρά, Μαρία, et al.. (2015). Mutation profile of KRAS and BRAF genes in patients with colorectal cancer: association with morphological and prognostic criteria. Genetics and Molecular Research. 14(4). 16793–16802. 8 indexed citations

10.

Vlachostergios, Panagiotis J. & Christos N. Papandreou. (2015). Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives. Frontiers in Oncology. 5. 6–6. 49 indexed citations

11.

Vlachostergios, Panagiotis J., Ioannis A. Voutsadakis, & Christos N. Papandreou. (2013). Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma. Cell Biology and Toxicology. 29(4). 199–211. 8 indexed citations

12.

Vlachostergios, Panagiotis J. & Christos N. Papandreou. (2013). Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis. Archives of Medical Science. 2(2). 307–310. 13 indexed citations

13.

Doumas, Stergios, et al.. (2012). Concomitant Thymic Carcinoma With Cervical and Supraclavicular Node Metastases and Thyroid Carcinoma: Report of a Case and Literature Review. Journal of Medical Cases. 3(3). 181–184.

14.

Vlachostergios, Panagiotis J., et al.. (2012). Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer. Journal of Negative Results in BioMedicine. 11(1). 2–2. 7 indexed citations

15.

Kouvaras, Evangelos, Christos N. Papandreou, Danai Daliani, Anastasios Athanasiadis, & George Κ. Koukoulis. (2011). Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in “thin” and “thick” tissue sections. The Breast. 21(1). 34–39. 6 indexed citations

16.

Papandreou, Christos N., Chrysoula Doxani, Panagiotis J. Vlachostergios, et al.. (2011). Evidence of Association Between Methylenetetrahydrofolate Reductase Gene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population. DNA and Cell Biology. 31(2). 193–198. 22 indexed citations

17.

Patrikidou, Anna, Panagiotis J. Vlachostergios, Ioannis A. Voutsadakis, et al.. (2011). Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell International. 11(1). 13–13. 17 indexed citations

18.

Ζιντζαράς, Ηλίας, et al.. (2010). Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer: a genetic association study and meta-analysis. Journal of Human Genetics. 55(11). 743–748. 14 indexed citations

19.

Vlachostergios, Panagiotis J., Anna Patrikidou, Danai Daliani, & Christos N. Papandreou. (2009). The ubiquitin‐proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation. Journal of Cellular and Molecular Medicine. 13(9b). 3019–3031. 15 indexed citations

20.

Papandreou, Christos N., B A Usmani, Yiping Geng, et al.. (1998). Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Medicine. 4(1). 50–57. 234 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact